Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | pTVG-AR |
| Synonyms | |
| Therapy Description |
pTVG-AR (MVI-118) is a DNA vaccine encoding the ligand binding domain of the androgen receptor (AR) that stimulates immune response against AR-expressing prostate cancer cells (PMID: 23108626, PMID: 32513836). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| pTVG-AR | MVI-118 | pTVG-AR (MVI-118) is a DNA vaccine encoding the ligand binding domain of the androgen receptor (AR) that stimulates immune response against AR-expressing prostate cancer cells (PMID: 23108626, PMID: 32513836). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02411786 | Phase I | pTVG-AR Sargramostim | A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF | Completed | USA | 0 |